Fritextsökning
Innehållstyper
-
ZEISS receives FDA clearance for INTRABEAM 700
With its new treatment platform for intraoperative radiotherapy, ZEISS is actively shaping the medical innovation of neuro tumor therapy.
-
Carl Zeiss Meditec achieves revenue growth and stable operating profit
Further recovery in order entry compared to prior year.
-
Ny generation glasrörsmätare för krävande miljöer
OEM Automatic erbjuder nu den uppgraderade GT1600-serien från Brooks Instrument – en robust och flexibel lösning för visuell flödesövervakning i industriella applikationer.
-
Strategic Clarity: The New Currency in Life Science
In an industry shaped by rapid regulatory changes and global competition, leading life science companies are rethinking what it takes to succeed. Increasingly, ...
-
Björn Arvidsson: ”We must raise our gaze to find the answers of the future”
A system approach isn't just about understanding complexity – it's about making better decisions. By seeing ourselves as part of larger systems, we can better a...
-
ZEN core now available for all ZEISS scanning electron microscopes
Introducing intuitive, streamlined SEM control over imaging, analytics, and multi-modal workflows.
-
Meet us at Control 2025
Innovations that drive efficiency.
-
u2-Lok – rostfria dubbelklämringskopplingar för trygg drift
I industriella miljöer där vätskor och gaser transporteras under högt tryck eller vakuum krävs pålitliga förbindelser. u2-Lok från Schwer Fittings, tillgänglig ...
-
Elekta föll efter rapport – men har fulla orderböcker
En lägre vinst än väntat fick strålbehandlingsbolaget Elekta att backa rejält på börsen. Samtidigt presenterades en stor order i Mexiko och ett nytt USA-samarbete.
-
Final assembly inspection of medical plastics
Technical paper by ZEISS Medical Industry Solutions.
-
Discover Precision: Join ZEISS at the Control Fair in Stuttgart
May 6-9, 2025 in Stuttgart. Hall 9, Booth 9309.
-
Positivt USA-besked om Alzecures smärtpreparat
Alzecure har beviljats särläkemedelsstatus i USA för smärtpreparatet ACD440.
-
Webinar: Can AI replace humans in pharmacovigilance?
The webinar will explore how AI can transform pharmacovigilance by enhancing efficiency, reducing errors, and addressing challenges such as software costs, data...
-
Medivir CEO on upcoming study: ”It's about working together with others”
Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks appr...
-
How to Assure Quality within R&D Medical Devices
Free webinar on June 3rd, 2025, 9:00 - 9:45 AM CEST and 5:00 - 5:45 PM CEST.
-
Quality assurance for research and development of medical devices
Overcome the hurdles of research, development, and QA lab environments within the regulated medical technology industry.
-
ZEISS Quality Innovations at CONTROL
May 6-9, 2025 in Stuttgart.
-
The art of successful licensing – “A lot has to align”
Sharp research, strong data and a high level of innovation are all very good, but more than that is required to achieve the goal of many biotechnology companies...
-
The new ZEISS Celldiscoverer 7 has been launched
Adaptable automation for advanced workflows.
-
Del 5 i Advance serien: Projektsupport & Driftsättning
Spirax Sarco säkerställer att alla system och komponenter levereras i full överensstämmelse med kundens operativa krav, från teknisk design och installation til...
-
Pneumatics Makes a Technological Leap with Piezo
The first high-precision proportional valve terminal VTEP opens up new application areas
-
KI’s new super machine measures brain activity in real-time – “A very expensive hairdo”
Using brand-new, super-advanced equipment, researchers at Karolinska Institutet can now measure brain activity in real-time, with higher resolution than previou...
-
Novo Nordisk appoints Mike Doustdar as new CEO
The Danish pharmaceutical giant Novo Nordisk has appointed Mike Doustdar as its new CEO. At the same time, the company announced it was lowering its forecasts –...
-
Eli Lilly requests re-examination of Alzheimer's drug recommendation
Eli Lilly has requested that the EMA re-examine its opinion on the company's Alzheimer's drug, Kisunla, the agency announced on Friday.
BREAKING